RapidPulse, Inc. secured $48 million in a Series B funding round led by Medtronic and top investors to support clinical trials and development of its next-generation stroke aspiration technology. The funds will complete the TURBO study and help seek FDA approval for their pulsed aspiration system designed to improve clot removal in acute ischemic stroke. This investment highlights strong confidence in RapidPulse's innovative approach to stroke treatment and positions the company for further clinical and regulatory progress.
Medtronic has completed its $650 million acquisition of SPR Therapeutics, a leader in short-term peripheral nerve stimulation (PNS) therapies for pain management. This acquisition adds SPR's FDA-cleared SPRINT® PNS System, a minimally invasive, non-o...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
